On Friday, Aaron’s, Inc. (NYSE:AAN)’s shares declined -6.55% to $34.93.
Aaron’s, Inc. (AAN), a leader in the sales and lease ownership and specialty retailing of furniture, consumer electronics, home appliances and accessories, recently declared revenues and earnings for the three and six months ended June 30, 2015.
For the second quarter of 2015, revenues raised 16.1% to $769.0 million contrast with $662.5 million for the second quarter of 2014. Net earnings raised to $40.5 million contrast with $8.5 million in the preceding year period. Diluted earnings per share were $.56 contrast with $.12 for the same quarter last year. EBITDA for the Company was $89.8 million contrast with $43.0 million a year ago.
On a non-GAAP basis, net earnings for the second quarter of 2015 raised to $44.7 million contrast with $27.2 million for the same period in 2014, and earnings per share assuming dilution raised to $.61 contrast with $.37 a year ago. In 2015, non-GAAP net earnings and diluted earnings per share exclude the effects of amortization expense resulting from the acquisition of Progressive. In 2014, in addition to Progressive amortization, non-GAAP results exclude the effects of certain one-time Progressive transaction costs, financial advisory and legal costs related to addressing planned matters and restructuring charges related to store closures. See “Use of Non-GAAP Information” and the related non-GAAP reconciliation accompanying this press release.
Aaron’s, Inc. operates as a specialty retailer of furniture, consumer electronics, computers, appliances, and household accessories in the United States and Canada. The company operates in five segments: Sales and Lease Ownership, Progressive, HomeSmart, Franchise, and Manufacturing. It engages in the lease ownership and retail sale of various products, counting flat-screen televisions, computers, tablets, living room, dining room and bedroom furniture, mattresses, washers, dryers and refrigerators.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares dropped -4.35% to $7.70.
Ariad Pharmaceuticals, Inc. (ARIA) declared long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of about 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of about 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. Eighty-three percent (83%) of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years.
Additionally, 95 percent of CP-CML patients who underwent ponatinib dose reductions maintained their responses (MCyR). Benefit-risk evaluations should guide the decision to initiate and maintain Iclusig therapy, particularly in patients who may be at raised risk for arterial occlusive events (AOE).
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors.
At the end of Friday’s trade, Halcon Resources Corp (NYSE:HK)‘s shares surged 3.02% to $0.927.
Halcón Resources Corporation (HK) declared plans to release its second quarter 2015 financial results on Thursday, July 30, 2015 after trading closes on the New York Stock Exchange.
The Company has also planned a conference call to talk about the release for Friday, July 31, 2015 at 10:00 a.m.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
Macy’s, Inc. (NYSE:M), ended its Friday’s trading session with -1.78% loss, and closed at $69.94.
Ongoing in its tradition of strengthening communities, Macy’s (M) has partnered with several extraordinary charity organizations for its first-ever Fashion Pass. From July 22 to Aug. 15, when you give $5 at the register, customers will receive 15 percent to 20 percent off storewide, plus $10 off a $30 purchase. One hundred percent of the $5 donation will benefit: Children’s Cancer Research Fund®, Council of Fashion Designers of America Foundation, Inc., The Elizabeth Taylor AIDS Foundation, Ronald McDonald House Charities® of Chicagoland & Northwest Indiana, Ronald McDonald House New York and The Fashion Incubators at Macy’s.
Macy’s has up-to-the-minute trends covered for fall—from ultra-sleek and minimalist to eclectic bohemian with international panache, to modernist athleisure and ultra-glamorous—and customers will be able to use their Fashion Pass to access the hottest designs at fabulous prices, all while supporting organizations that do life-changing work.
Macy’s, Inc., together with its auxiliaries, operates stores and Internet Websites in the United States. Its stores and Websites sell a range of merchandise, counting apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates Bloomingdale’s Outlet stores that offer a range of apparel and accessories, counting women’s ready-to-wear, fashion accessories, jewelry, handbags, and intimate apparel, in addition to men’s, children’s, and women’s shoes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
